Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies

Respiratory syncytial virus (RSV) has a major role in respiratory infections in young infants around the world. However, substantial progress has been made in recent years in the field of RSV. A wide variety of observational studies and clinical trials published in the past decade provide a thorough...

Descripción completa

Detalles Bibliográficos
Autores principales: Dvorkin, Julia, De Luca, Julián, Alvarez-Paggi, Damian, Caballero, Mauricio T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888399/
https://www.ncbi.nlm.nih.gov/pubmed/36733921
http://dx.doi.org/10.2147/IDR.S373584
_version_ 1784880524795314176
author Dvorkin, Julia
De Luca, Julián
Alvarez-Paggi, Damian
Caballero, Mauricio T
author_facet Dvorkin, Julia
De Luca, Julián
Alvarez-Paggi, Damian
Caballero, Mauricio T
author_sort Dvorkin, Julia
collection PubMed
description Respiratory syncytial virus (RSV) has a major role in respiratory infections in young infants around the world. However, substantial progress has been made in recent years in the field of RSV. A wide variety of observational studies and clinical trials published in the past decade provide a thorough idea of the health and economic burden of RSV disease in the developing world. In this review, we discuss the impact of RSV burden of disease, major gaps in disease estimations, and challenges in generating new therapeutic options and an immune response against the virus, and briefly describe next generation technologies that are being evaluated.
format Online
Article
Text
id pubmed-9888399
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98883992023-02-01 Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies Dvorkin, Julia De Luca, Julián Alvarez-Paggi, Damian Caballero, Mauricio T Infect Drug Resist Review Respiratory syncytial virus (RSV) has a major role in respiratory infections in young infants around the world. However, substantial progress has been made in recent years in the field of RSV. A wide variety of observational studies and clinical trials published in the past decade provide a thorough idea of the health and economic burden of RSV disease in the developing world. In this review, we discuss the impact of RSV burden of disease, major gaps in disease estimations, and challenges in generating new therapeutic options and an immune response against the virus, and briefly describe next generation technologies that are being evaluated. Dove 2023-01-27 /pmc/articles/PMC9888399/ /pubmed/36733921 http://dx.doi.org/10.2147/IDR.S373584 Text en © 2023 Dvorkin et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Dvorkin, Julia
De Luca, Julián
Alvarez-Paggi, Damian
Caballero, Mauricio T
Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies
title Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies
title_full Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies
title_fullStr Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies
title_full_unstemmed Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies
title_short Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies
title_sort responding to higher-than-expected infant mortality rates from respiratory syncytial virus (rsv): improving treatment and reporting strategies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888399/
https://www.ncbi.nlm.nih.gov/pubmed/36733921
http://dx.doi.org/10.2147/IDR.S373584
work_keys_str_mv AT dvorkinjulia respondingtohigherthanexpectedinfantmortalityratesfromrespiratorysyncytialvirusrsvimprovingtreatmentandreportingstrategies
AT delucajulian respondingtohigherthanexpectedinfantmortalityratesfromrespiratorysyncytialvirusrsvimprovingtreatmentandreportingstrategies
AT alvarezpaggidamian respondingtohigherthanexpectedinfantmortalityratesfromrespiratorysyncytialvirusrsvimprovingtreatmentandreportingstrategies
AT caballeromauriciot respondingtohigherthanexpectedinfantmortalityratesfromrespiratorysyncytialvirusrsvimprovingtreatmentandreportingstrategies

Ejemplares similares